PARTICIPATION IN THE PEDIATRIC ONCOLOGY GROUP

参与儿科肿瘤学小组

• 批准号: 3558411
• 负责人: RONALD L DUBOWY
• 金额: $ 6.15万
• 依托单位: UPSTATE MEDICAL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-01-01 至 1995-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3558411
• 关键词: child (0-11); clinical trials; cooperative study; human subject; human therapy evaluation; pediatric neoplasm /cancer

This proposal requests continued funding to support the Pediatric Oncology program of the State University of New York (SUNY). Health Science Center at Syracuse, in its participation within the Pediatric Oncology Group (POG). The institutional program in Pediatric Oncology Is an interdisciplinary one, involving the Departments of Radiation Oncology, Pediatric Surgery, Pathology, Immunology, Neurosurgery, and Neurology, as well as the Division of Pediatric Hematology-Oncology. Funding of the Syracuse program will permit the continuation of its excellent record of evaluable patient entry onto POG studies. It will also allow the continuation of its investigators' significant scientific and administrative contributions to POG. Syracuse faculty have played key roles in developing and coordinating protocols #8849 (hydroxyurea-araC in refractory leukemia), #8823/24 (alpha interferon In CML), and #8973 (etoposide plus continuous infusion carboplatin in refractory leukemia). New protocols to be initiated from this institution will include a combination interferon-chemotherapy protocol for ACML, and a laboratory study utilizing an assay for TdT RNA in remission marrow specimens from patients with ALL, in which preliminary findings, relating the presence of elevated values to subsequent reslapse, will be tested prospectively. The active participation of Syracuse investigators on many POG committees, particularly that of the Data Manager, will be made possible by continuation of funded support.

该提案要求继续提供资金，以支持儿科 纽约州立大学（SUNY）的肿瘤学项目。 健康 锡拉丘兹科学中心，参与儿科 肿瘤组（POG）。 儿科肿瘤学的机构计划是 一个跨学科的，涉及辐射部门 肿瘤学、小儿外科学、病理学、免疫学、神经外科学和 神经科，以及儿科血液肿瘤科。 锡拉丘兹计划的资金将允许其继续 POG研究中可评价患者的良好记录。 它将 也允许其研究人员继续进行重要的科学研究， 以及对POG的行政捐款。 锡拉丘兹的教职员工 在开发和协调方案中的关键作用#8849 （羟基脲-araC在难治性白血病中的应用），#8823/24（α干扰素在 CML）和#8973（依托泊苷加持续输注卡铂， 难治性白血病）。 由此启动新协议 机构将包括干扰素-化疗联合方案 和一项利用TdT RNA测定法进行的实验室研究， 急性淋巴细胞白血病患者的缓解期骨髓标本，其中初步 结果，将升高值的存在与随后的 将进行前瞻性测试。 的积极参与 锡拉丘兹的调查人员在许多POG委员会，特别是 数据管理员，将通过继续提供资金支持而成为可能。